A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)

Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed. The two substances are: palonosetron, an antagonist of 5 HT3 receptors, and fosnetupitant, an antagonist of NK1 receptors that transforms into netupitant in the body. The medication is administered through intravenous injection (IV- drip).
This study is built from 2 parts:
Part 1: phase 2, open label Part 2: phase 3 double blind
The detailed description, study design, study milestones and eligibility criteria will reflect the Part 1 requirements

开始日期2025-04-28

申办/合作机构

Helsinn Healthcare SA

ChiCTR2500101568

/ SuspendedN/AIIT

NEPA and dexamethasone for preventing of chemotherapy induced nausea and vomiting in colorectal cancer patients with high risk factors receiving moderately emetogenic chemotherapy, a single-center experience

开始日期2025-04-27

申办/合作机构

北京大学深圳医院（北京大学深圳临床医学院）

ChiCTR2400093323

/ Recruiting临床4期IIT

Study on gastrointestinal adverse reactions associated with myelopathic chemotherapy treated by Netopitam-palonosetron combined with fennel kosher salt acupoint hot compress

开始日期2024-12-02

申办/合作机构-

100 项与奈妥匹坦帕洛诺司琼相关的临床结果

登录后查看更多信息

100 项与奈妥匹坦帕洛诺司琼相关的转化医学

登录后查看更多信息

100 项与奈妥匹坦帕洛诺司琼相关的专利（医药）

登录后查看更多信息

124

项与奈妥匹坦帕洛诺司琼相关的文献（医药）

2025-06-01·SUPPORTIVE CARE IN CANCER

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy—the DANGER-emesis study

Article

作者: Detlefsen, Sofie S ; Jørgensen, Trine L ; Herrstedt, Jørn ; Knudsen, Anja Ø ; Andersen, Ditte S ; Ruhlmann, Christina H ; Möller, Sören ; Nøttrup, Trine J ; Nyvang, Gitte-Bettina

Abstract:

Purpose:

Netupitant 300 mg/palonosetron 0.5 mg (NEPA) would be ideal as antiemetic prophylaxis for patients receiving weekly cisplatin, as it would reduce concurrent medication intake compared to the 3-day aprepitant regimen. However, due to the longer half-life of netupitant (~ 88 h), weekly administration could potentially lead to accumulation and toxicity. This study aims to investigate the safety and antiemetic efficacy of weekly administration of NEPA plus dexamethasone (DEX) in patients treated for cervical cancer with radiotherapy and weekly cisplatin 40 mg/m2.

Methods:

This single-arm, open-label, phase II study evaluated patients with cervical cancer receiving NEPA and DEX before weekly cisplatin and concomitant radiotherapy for up to 5 weeks. Safety was assessed during weekly adverse event (AE) assessments. Efficacy was evaluated using Patient Diaries reporting daily nausea, vomiting, and use of rescue medication during the study period.

Results:

Between October 8, 2018, and January 2, 2024, 73 patients were recruited from two Danish departments of oncology; 37 completed all five weekly cycles. The majority of AEs were of mild or moderate intensity, with fatigue being the most frequently observed (95% of patients). Seven (10%) patients encountered ≥ 1 grade 3 treatment-related AEs (TRAEs). No grade 4 TRAEs or deaths were observed. In terms of efficacy, no vomiting and no nausea days 1–35 were 86% and 18%, respectively. Mean time to first emetic episode was 9 days.

Conclusion:

Weekly NEPA administration was safe, well-tolerated, and highly effective during concomitant radiotherapy and weekly cisplatin.

Trial registration:

This trial is registered at ClinicalTrials.gov (NCT03668639-2018–09-10).

2025-04-21·Future Oncology

Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates

Review

作者: Schwartzberg, Lee ; Bianchini, Giampaolo ; Vidal, María ; Roeland, Eric J. ; Cortés, Javier ; Aapro, Matti ; Jordan, Karin ; Navari, Rudolph M. ; Rugo, Hope S. ; Scotté, Florian ; Iihara, Hirotoshi ; Park, Yeon Hee ; Licata, Luca

Nausea and vomiting are common, distressing side effects associated with chemotherapeutic regimens, resulting in reduced quality of life and treatment adherence. Appropriate antiemetic prophylaxis strategies may reduce/prevent chemotherapy-induced nausea and vomiting (CINV). Historically, investigators assessed antiemetics up to 120 hours after chemotherapy. However, CINV can extend beyond this time. Thus, the effect of antiemetics during the long-delayed period (>120 hours) requires investigation. Emerging treatment options, including certain antibody-drug conjugates (ADCs), are associated with high rates of acute and late-onset nausea and vomiting that can last for extended duration. With the increasing number of ADCs approved and in development, there is urgency to control nausea and vomiting in patients receiving these new therapies. In this narrative review, we present the emetogenic potential of ADCs and CINV in the long-delayed period along with antiemetic prophylaxis strategies used to date. We also discuss the promising role of the fixed-combination antiemetic NEPA ([fos]netupitant plus palonosetron) in controlling long-delayed nausea and vomiting, addressing characteristics that may contribute to its longer efficacy duration compared to other antiemetics. Finally, we highlight encouraging results with NEPA in patients receiving the ADCs trastuzumab deruxtecan or sacituzumab govitecan, which suggest NEPA may be an effective antiemetic prophylaxis in these settings.

2025-04-01·ARCHIVES OF GERONTOLOGY AND GERIATRICS

Comparison of non-exercise physical activity and exercise habits for preventing frailty among community-dwelling older adults: A 7-year follow-up from the Kashiwa cohort study

Article

作者: Iijima, Katsuya ; Lyu, Weida ; Yoshizawa, Yasuyo ; Son, Bo-Kyung ; Tanaka, Tomoki

BACKGROUND:

Engagement in non-exercise physical activities (NEPA) has a significant correlation with health. This study aimed to compare the impact of moderate-to-vigorous-intensity NEPA and exercise habit (EH) on frailty among community-dwelling older adults.

METHODS:

This study utilized data from the Kashiwa cohort study in Japan, with baseline assessments in 2014 with a 7-year follow ups (4.0 [2.0-7.0]). A total of 1,288 participants were included. Frailty was assessed using the Cardiovascular Health Study Index, NEPA through the Global Physical Activity Questionnaire, and EH via self-reported exercise engagement at each follow-up examination. Generalized estimating equations (GEE) and Cox regression analyses were used to estimate associations between NEPA, EH, and frailty.

RESULTS:

Compared to participants with no NEPA nor EH, those with NEPA only, with EH only, and with both showed significantly lower adjusted odds ratio (95 %CI) of frailty: 0.29 (0.16-0.52), 0.21 (0.11-0.41) and 0.21 (0.12-0.36). NEPA and EH at baseline were predictor variables for new-onset frailty during the 7-year follow-up period, with adjusted hazard ratios (95 % CI) of 0.55 (0.33-0.92) for NEPA only, 0.51 (0.29-0.90) for EH only, and 0.42 (0.25-0.70) for both. No significant differences were observed between the associations of NEPA and EH with frailty.

CONCLUSIONS:

NEPA is associated with lower frailty risk in older adults, with a similar but non-additive effect to that of EH. These findings highlight the importance of NEPA for frailty prevention, particularly for those not engaged in formal exercise programs.

项与奈妥匹坦帕洛诺司琼相关的新闻（医药）

2025-05-16

·药事纵横

2024年A股上市药企研发费用TOP100

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。我们根据2024年财报，按照申万行业分类，统计了A股医药生物上市公司研发费用TOP100情况如下：排名前5的是百济神州-U(688235)、恒瑞医药(600276)、迈瑞医疗(300760)、复星医药(600196)、上海医药(601607)。2024年研发费用支出超过20亿元的有7家公司，超过10亿元的有10家公司。百济神州-U(688235)：2024年研发费用支出141.4亿元，同比增长10.35%，占总营收的52%。恒瑞医药（600276）2024年研发费用支出65.83亿元，同比大幅增长32.88%，占总营收23.52%。复星医药(600196)：2024年实现营业收入410.67亿元，同比下降0.8%；实现净利润27.70亿元，同比增加16.08%。2024年公司研发费用支出36.44亿元，同比下降16%。其中，创新产品收入稳步增长，核心品种创新型抗PD-1单抗斯鲁利单抗注射液（中国境内商品名：汉斯状）、CAR-T细胞治疗产品奕凯达（阿基仑赛注射液）、止吐药物奥康泽（奈妥匹坦帕洛诺司琼胶囊）以及长效重组人粒细胞集落刺激因子产品珮金（拓培非格司亭注射液）、心衰和高血压治疗药物一心坦（沙库巴曲缬沙坦钠片）均实现较快增长。上海医药（601607）2024年公司实现营业收入2,752.51亿元，同比增长 5.75%。其中：医药工业实现销售收入237.31亿元，同比下降9.62%；医药商业实现销售收入2,515.20亿元，同比增长7.47%。报告期内，公司实现归属于上市公司股东的净利润45.53亿元，同比上升20.82%。2024年公司研发费用支出23.94亿元，占制药工业端营收比拟为10.08%。2024年公司临床申请获得受理及进入后续临床研究阶段的新药管线已有 54 项，其中创新药40 项（含美国临床II 期1 项），改良型新药14 项。在创新药管线中，已有1 项提交上市申请，5 项处于临床III 期阶段。创新药板块值得关注的还有百利天恒(688506)和荣昌生物(688331)。百利天恒(688506)2024年研发费用支出14.43亿元，同比大增93%；研发费用占营收比拟为24.78%。2024年公司实现收入 58.23 亿元，同比增长936.3%，扣非归母净利润36.36 亿元。公司收入大幅增长并实现盈利，主因与 BMS 就 BL-B01D1 达成合作协议的8亿美元首付款到账。荣昌生物(688331)2024年研发费用支出15.4亿元，同比增长17.87%，研发费用占营收比拟高达89.69%。2024年实现营业收入17.17 亿元，同比增长58.54%，主要是因为 2024 年两个核心产品泰爱（泰它西普）、爱地希（维迪西妥单抗）销售收入及销量同比快速增长，扣非后净亏损 15.08 亿元，扣非后净利润仍为负数主要由于公司对在研项目研发投入仍然较大以及对商业化产品泰它西普和维迪西妥单抗的推广力度的加大。CXO板块：药明康德、普洛和凯莱英研发费用相对较高随着2024年以来海外新药投融资逐渐回暖、国内政策端支持创新药合理定价鼓励高质量创新，下游需求正逐渐恢复，CXO行业已开始进入复苏阶段，以药明康德、康龙化成、凯莱英为代表的头部CXO企业2025Q1业绩同环比改善明显，边际拐点趋势已现。截止2024 年末，药明康德(603259)整体活跃客户约6,000 家。其中，持续经营业务截至年末活跃客户约5,500家，持续经营业务全年新增客户约1,000 家，全球各地客户对公司服务的需求持续增长。2024年公司研发费用支出12.39亿元，同比下降14%。药明康德的研发费用支出在A股CXO板块排名第一。公司2025年Q1实现营业收入96.55亿元，同比增长20.96%，归母净利润36.72亿元，同比增长89.06%，归母扣非净利润23.29亿元，同比增长14.50%。截至2025年3月末，药明康德(603259)持续经营业务在手订单523.3亿元，同比增长47.1%。普洛药业(000739)公司依托深耕多年的原料药中间体业务基础，现已拓展成为兼具原料药中间体、CDMO、药品和医美原料药四项业务，具备丰富的产品类型，涵盖多个治疗领域，可满足众多客户的各种相关研发、生产和服务。2024年公司实现营业收入120.22亿元，同比增长4.77%；实现净利润10.31亿元，同比下降 2.29%；其中公司原料药中间体业务实现销售收入86.51亿元，同比增长8.32%；创新药研发生产服务（CDMO）板块2024年实现营收18.84亿元，占比15.67%。相比2023年20亿元的收入，同比下降6.05%。公司现有研发人员1156 名，其中博士54 名，硕士405 人。2024年公司研发费用6.41亿元，同比增长2.66%，占营业收入的5.34%。凯莱英(002821):截止3 月28 日，在手订单达10.5 亿美元，同比增长20%。2024年公司研发费用支出6.15亿元，同比下降13%。2024年实现收入58.05亿元同比下降25.82%，归母净利润9.49 亿元同比下降58.17%。值得关注的是公司的合成生物技术业务板块，收入同比增长33.22%，收入来源的80%以上为境外客户，接触新客户近100 家。2025年Q1 公司实现营收15.4 亿元，同比增长10%，实现归母净利润3.3 亿元，同比增长15.8%。医疗器械：迈瑞和联影医疗研发投入靠前迈瑞医疗(300760)：2024年公司研发费用支出36.66亿元，同比增长6.79%，占总营收10%，公司是A股上市医疗器械板块研发投入最高的公司。2024年公司实现营业收入367.26亿元元，较上年同期增长5.14%；实现净利润 116.68亿元，较上年同期增长 0.74%；研发费用支出36.66亿元，同比增长6.79%。公司主要产品覆盖三大业务领域：生命信息与支持、体外诊断以及医学影像，拥有国内同行业中最全的产品线，以安全、高效、易用的“一站式”产品和数智化解决方案满足临床需求。历经多年的发展，迈瑞医疗已经成为全球领先的医疗器械以及解决方案供应商，产品远销全球 190 多个国家及地区。联影医疗(688271)：2024年研发费用支出17.61亿元，同比增长1.9%，研发投入占营业收入的比例21.95%。2024年公司实现营业收入为103亿元，同比下降9.73%。2024 年度，通过纵深推进“高举高打，一核多翼”的全球化战略，公司实现海外业务营业收入22.66 亿元，同比增长35.07%，占总体营业收入22.00%的历史新高，取得高端市场突破与新兴区域渗透的双重战略成果。资料来源：各公司公告

财报免疫疗法细胞疗法临床3期引进/卖出

2025-04-16

·复星医药

全国肿瘤防治宣传周｜复星医药整合创新为肿瘤防治注入新动能

国家癌症中心最新统计数据显示，‌我国每年新发肿瘤患者超482万例，癌症死亡病例约257万，占全球总量的近四分之一。恶性肿瘤不仅成为威胁居民健康的首要因素，更让无数家庭深陷治疗费用高昂、优质医疗资源稀缺、罕见肿瘤药物“一药难求”的困境。作为全球领先的创新医疗整合者，复星医药始终以“让每个家庭乐享健康”为目标，多年来坚持创新研发，在实体瘤、血液瘤、肿瘤支持治疗、罕见病肿瘤等细分领域持续深耕，积极探索，为全球患者提供创新可及的产品和服务。2025年4月15日—21日是第31届全国肿瘤防治宣传周，本次宣传周的主题为“科学防癌，健康生活”。在此期间，复星医药携手全国近百位知名肿瘤专家，围绕支持治疗、罕见病肿瘤、淋巴瘤三大领域，通过线上线下数十场科普患教会、专家义诊，以及专家访谈、科普视频、图文资讯等多种形式，多渠道普及防癌抗癌知识技能，倡导健康生活方式，持续提升公众科学防治能力，为健康中国建设注入科技动能。淋巴瘤基石长青利享安康，利妥昔单抗守护生命之光科学治疗淋巴瘤的关键在于“精准分型、个体化方案”，而淋巴瘤因分型复杂、复发率高，长期面临治疗瓶颈，致使患者比其他实体瘤患者承受更频繁的身心煎熬和经济负担，长期生存率及生活质量仍待进一步提升。利妥昔单抗作为首个用于淋巴瘤治疗的单克隆抗体，开创了免疫化疗的新纪元。在CD20靶向治疗领域，尽管新型单抗药物不断涌现，市场竞争日趋激烈，利妥昔单抗凭借其20余年临床验证的疗效和安全性，始终保持着不可替代的基石地位。复星医药自主研发的中国首个自研CD20单抗利妥昔单抗的诞生，标志着中国生物类似药研发实现“零的突破”，为非霍奇金淋巴瘤、慢性淋巴细胞白血病等患者带来了新的治疗方案，明显提高了药物可及性，极大地减轻了患者的经济负担，让医保支出得以高效利用。利妥昔单抗注射液是中国迄今首个且唯一同时拥有淋巴瘤及类风湿关节炎双领域适应证的利妥昔单抗，上市6年以来，已惠及众多中国患者。利妥昔单抗注射液Ⅲ期研究证实，该药与参照药短期疗效及安全性等同；5年随访结果证实，该药长期疗效及安全性与参照药等同；真实世界研究证实，该药与参照药真实世界数据及其Ⅲ期研究数据结果一致。全国肿瘤防治宣传周活动预告淋巴瘤之家-线上公益面对面时间：4月10日-15日地点：线上义诊依托淋巴瘤之家开展线上义诊公益活动，为淋巴瘤患者树立淋巴瘤疾病的规范化治疗的正确认识，推动淋巴瘤治疗的可愈可及。线上义诊持续5天，10位大咖将为患者朋友提供专业的咨询，针对疾病相关问题，制定个性化的、专业化的疾病指导。 “点亮星光愈你同行”线下淋巴瘤科普患教活动时间：4月15日-21日地点：全国20家医院为淋巴瘤患者树立规范治疗意识，提高患者治疗信心的“点亮星光愈你同行”科普患教活动同步启动，将依托CACA线下示范点，开展淋巴瘤患者科普教育活动。上海复旦大学附属肿瘤医院、中国医学科学院血液病医院在内的全国20家知名医院的专家学者将在多地开展线下科普宣教和互动答疑，服务广大淋巴瘤患者。肿瘤支持治疗从“延寿”到“优活”，破解治疗依从性难题肿瘤患者的“健康生活”不仅在于疾病的预防和预后管理，更需关注治疗期的患者生存质量。支持治疗通过精准管理肿瘤治疗过程中的不良反应，助力患者获得足剂量、足疗程的治疗，完成既定的治疗周期，让患者从生存迈向生活。针对肿瘤患者在化疗过程中的常见不良反应——化疗所致恶心和呕吐（CINV），复星医药推出全球首个且目前唯一已上市同时阻断5-HT3受体和NK-1受体双通道的口服止吐药物奈妥匹坦帕洛诺司琼胶囊，同时覆盖所有HEC和MEC方案，半衰期长达96小时，给予患者“急性期”与“延迟期”全程保护。针对抗肿瘤治疗最常见的血液学毒性——中性粒细胞减少症，由厦门特宝研发，复星医药商业化的我国首个Y型PEG-rhG-CSF，也是“十一五”国家科技重大专项认证的治疗用生物制品1.1类创新药拓培非格司亭注射液，能够预防中性粒细胞减少症及FN的发生。在宣传周期间，由中国抗癌协会发起，复星医药支持的多项肿瘤支持治疗主题活动正在如火如荼进行中，敬请关注！全国肿瘤防治宣传周活动预告中国抗癌协会-线上专家义诊时间：4月16日 19:00-20:30《全程管理·全息发力：抗肿瘤药物不良反应患者宣教和线上答疑》将针对抗肿瘤药物恶心呕吐及骨髓抑制防治的话题，多位肿瘤专家将为患者提供个体化管理方案，涵盖症状控制、营养支持、心理疏导等全周期支持治疗，助力患者顺利完成治疗周期，改善生活质量，提高治疗耐受性，实现最佳临床获益。中国抗癌协会-支持治疗频道科普视频发布时间：4月15日-21日南方医科大学珠江医院李玉华教授、北京大学国际医院党委书记、院长梁军教授、复旦大学附属肿瘤医院任玉兰教授等多位专家将围绕‌血液肿瘤、消化肿瘤及妇科肿瘤‌患者的‌抗肿瘤药物不良反应管理‌与‌肿瘤支持治疗‌策略进行科普，并录制科普视频，视频将发布于中国抗癌协会APP及大众媒体，助力患者科学抗癌。中国抗癌协会-29场院内患者教育活动时间：4月15日-21日29家权威医院开展线下患教活动，专家现场答疑，重点讲解‌抗肿瘤药物不良反应管理‌与‌肿瘤支持治疗‌策略，帮助患者科学应对治疗挑战，提升生存质量，让每位患者真正获益！罕见病肿瘤复创之光沃领新生，“无人区”迎来曙光科学防癌的关键在于“早发现、早干预”，而罕见肿瘤因发病率低、诊断困难，长期面临治疗空白，致使罕见病肿瘤患者比其他癌症患者承受更大的身心折磨和经济压力，生存质量长期难以得到保证。2024年5月，国家药监局药品审评中心受理了复星医药自主研发的创新型MEK1/2抑制剂芦沃美替尼片的上市申请，其用于治疗成人树突状细胞和组织细胞肿瘤，以及用于治疗2岁及2岁以上儿童1型神经纤维瘤病相关的丛状神经纤维瘤的两个适应证均已被纳入优先审评，这不仅为罕见病患者提供了新的治疗选择，也有望使复星医药成为国内唯一一个拥有儿童NF1和成人组织细胞肿瘤的靶向药物的企业。芦沃美替尼片的多项临床数据已在ASCO及EHA等全球性学术会议上发布，展现出令人鼓舞的疗效且耐受性良好，获得积极反响。其II期临床研究结果显示，芦沃美替尼片与同类药物相比疗效一致，但起效更快，疼痛强度降低程度更高，且该药TRAE导致的药物暂停率低，无剂量下调/永久停药，消化道不良反应、乏力、发热、射血分数明显更优，适应人群更大。全国肿瘤防治宣传周活动预告“复罕心声，愈见希望”‌系列专家访谈时间：4月18日地点：北京&南京复星医药“复罕心声” 系列专家访谈也将同期启动，南京儿童医院血液科方拥军教授与北京儿童医院血液科张蕊教授将聚焦儿童罕见血液肿瘤领域，开展疾病科普并分享最新诊疗进展。作为一家植根中国、创新驱动的全球化医药健康产业集团，复星医药多年来以患者为中心、临床需求为导向，深耕肿瘤治疗领域，持续投入研发，从诊断到治疗，全产业链布局肿瘤生态，为肿瘤患者提供更可负担的治疗方案和全方位的健康保障，持续为我国肿瘤防治事业贡献力量。“每一个突破背后，都是患者一份生的希望。”从实验室到临床，从新药到新方案，中国肿瘤防治事业正以科技之力，为生命点亮更多可能。审批号:P-20250415-002

生物类似药临床3期

2025-04-02

·GlobeNewswire-Health Care

Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)

Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced the submission of a new formulation for AKYNZEO® to the European Medicines Agency (EMA). AKYNZEO® is indicated for the prevention of acute and delayed nausea and vomiting associated with both highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy. Once approved, this new innovative formulation may offer benefits to cancer patients in addition to the already approved formulations. The new AKYNZEO® formulation is expected to be launched in H1 2026. Roberta Cannella, Chief Technical Officer, commented: “This submission brings us closer to offering patients a new option for AKYNZEO®. It not only demonstrates our commitment to enhancing patients’ quality of life but also our dedication to innovation in supportive care.” About AKYNZEO® AKYNZEO® is the first and only 5-HT3 and NK1 receptor antagonist fixed dose combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. For additional information please see the EU Summary of Product Characteristics. About Helsinn Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and a consolidated network of partners to reach out to patients in more than 190 countries worldwide. Established in 1976, Helsinn is a fourth-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision. To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X. For more information: Helsinn Group Media Contact:Sabrina PerucchiGroup Communication ManagerLugano, Switzerland Tel: +41 (0) 91 985 21 21 Email: Info-hhc@helsinn.com

上市批准

100 项与奈妥匹坦帕洛诺司琼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	奈妥匹坦帕洛诺司琼	A04AA	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶心	加拿大	Knight Therapeutics, Inc.	2017-11-20
呕吐	加拿大	Knight Therapeutics, Inc.	2017-11-20
化疗引起的恶心和呕吐	美国	Helsinn Healthcare SA	2014-10-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	美国	Helsinn Healthcare SA	2018-03-16
乳腺癌	临床3期	格鲁吉亚	Helsinn Healthcare SA	2018-03-16
肾母细胞瘤	临床2期	希腊	Helsinn Healthcare SA	2025-04-28
肾母细胞瘤	临床2期	波兰	Helsinn Healthcare SA	2025-04-28
肾母细胞瘤	临床2期	罗马尼亚	Helsinn Healthcare SA	2025-04-28
肾母细胞瘤	临床2期	土耳其	Helsinn Healthcare SA	2025-04-28
脑癌	临床2期	美国	Helsinn Healthcare SA	2017-08-31
脑癌	临床2期	俄罗斯	Helsinn Healthcare SA	2017-08-31
脑癌	临床2期	塞尔维亚	Helsinn Healthcare SA	2017-08-31
脑癌	临床2期	乌克兰	Helsinn Healthcare SA	2017-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2025	N/A	鼻咽癌	312	Oral NEPA	餘顧壓餘醖憲獵範遞網(壓繭壓鏇遞網願衊壓鬱) = 鏇蓋鹹遞餘醖繭願獵鹹觸醖蓋壓衊鹹獵醖餘選 (廠衊鹹憲壓顧鬱鑰鑰顧 ) 更多	积极	2025-05-30
				Fosaprepitant + Palonosetron	餘顧壓餘醖憲獵範遞網(壓繭壓鏇遞網願衊壓鬱) = 繭選鹽襯顧艱糧鹹廠鹹觸醖蓋壓衊鹹獵醖餘選 (廠衊鹹憲壓顧鬱鑰鑰顧 ) 更多
ASCO2025	临床3期	化疗引起的恶心和呕吐	164	Dexamethasone 5mg	醖製簾鬱築糧蓋築襯廠(齋餘網廠遞憲觸憲壓鑰) = 夢遞選構積夢選觸構艱蓋壓壓餘構簾願廠觸鹽 (鹹憲鑰簾糧壓構襯餘範 ) 更多	积极	2025-05-30
				Dexamethasone 8mg	醖製簾鬱築糧蓋築襯廠(齋餘網廠遞憲觸憲壓鑰) = 窪糧範鹹製獵鏇顧選憲蓋壓壓餘構簾願廠觸鹽 (鹹憲鑰簾糧壓構襯餘範 ) 更多
ASCO_GI2025	N/A	化疗引起的中毒	2,079	NEPA (Netupitant/Palonosetron)	醖壓觸衊壓構壓鏇壓夢(構築淵淵遞鹹積鹹鬱窪): RR = 1.07 (95% CI, 1.01 ~ 1.13), P-Value = 0.01 更多	积极	2025-01-23
				Aprepitant (APR)
ESMO_ASIA2024	N/A	-	-	NEPA 300mg on day 1,5	構鹽襯積憲壓遞網繭醖(選構糧糧夢餘鏇鏇遞築) = 衊夢築憲廠夢觸鹹繭淵廠遞醖襯網顧鹽鑰窪糧 (網觸膚夢憲選壓衊範獵 ) 更多	积极	2024-12-07
				NEPA 300mg on day 1	構鹽襯積憲壓遞網繭醖(選構糧糧夢餘鏇鏇遞築) = 廠夢窪鏇選願範艱願願廠遞醖襯網顧鹽鑰窪糧 (網觸膚夢憲選壓衊範獵 ) 更多
ESMO_ASIA2024	N/A	肿瘤	164	NEPA	艱衊襯製襯壓蓋鹹襯鑰(蓋願簾襯蓋憲膚製齋簾) = 糧鬱選艱蓋夢淵鹽範鏇獵壓淵壓窪醖夢齋範壓 (醖壓選鹽選壓築淵壓鹹 ) 更多	积极	2024-12-07
CTRI/2023/04/051951 (ASCO2024) 人工标引	临床4期	化疗引起的恶心和呕吐	178	IntraVenous (Fos)NEtupitant and Palonosetron (IV NEPA) (HEC)	範鹽鬱網淵襯鑰憲夢廠(簾蓋製襯壓範廠淵襯鏇) = 繭餘積壓網網製鑰繭築醖鹹憲膚繭願膚鏇鏇蓋 (夢餘憲範壓餘顧範觸繭 ) 更多	积极	2024-05-24
				IntraVenous (Fos)NEtupitant and Palonosetron (IV NEPA) (MEC)	範鹽鬱網淵襯鑰憲夢廠(簾蓋製襯壓範廠淵襯鏇) = 鑰膚鏇淵繭製鑰衊鹽齋醖鹹憲膚繭願膚鏇鏇蓋 (夢餘憲範壓餘顧範觸繭 ) 更多
EHA2023	N/A	造血干细胞移植 \| 淋巴瘤	76	NEPA	積衊窪簾夢鏇願築鬱築(艱憲觸膚願顧築繭鬱鬱) = 選憲淵餘觸鏇願齋構醖獵憲鏇窪壓簾艱鑰膚壓 (顧鏇齋糧夢積糧選觸獵 ) 更多	-	2023-06-08
				Ondansetron	積衊窪簾夢鏇願築鬱築(艱憲觸膚願顧築繭鬱鬱) = 觸憲簾蓋齋範壓獵淵觸獵憲鏇窪壓簾艱鑰膚壓 (顧鏇齋糧夢積糧選觸獵 ) 更多
NCT04201769 (Pubmed)	临床3期	化疗引起的恶心和呕吐 \| 非小细胞肺癌 \| 呕吐	228	NEPA plus no further DEX	壓艱獵襯淵遞獵餘憲範(醖蓋憲餘齋鹹範憲選遞) = 艱觸顧艱壓齋繭範膚簾廠糧夢鹹淵夢艱淵鏇壓 (獵襯鑰鬱艱蓋壓鬱襯憲, 59.7 ~ 86.8) 更多	积极	2023-06-06
				NEPA plus oral low-dose DEX (4 mg) on days 2-3	壓艱獵襯淵遞獵餘憲範(醖蓋憲餘齋鹹範憲選遞) = 簾壓蓋鹹廠憲夢鹹選廠廠糧夢鹹淵夢艱淵鏇壓 (獵襯鑰鬱艱蓋壓鬱襯憲, 62.5 ~ 92.6) 更多
CTRI/2020/02/023586 (ASCO2023)	临床4期	恶心 \| 恶心和呕吐 \| 呕吐	354	NEPA (NEtupitant 300mg and PAlonosetron 0.50 mg)	遞壓淵顧遞蓋膚製襯廠(鏇獵襯顧醖繭積顧遞膚) = Adverse events were reported in 10 (3.4%) patients, with leg pain being the most common 3(0.8%) 廠遞艱觸蓋獵鹹窪鹹餘 (窪憲襯網齋積鹽糧膚繭 )	积极	2023-05-31
P543 (EBMT2023)	N/A	-	70	NEPA and low dose of dexamethasone	構遞膚廠餘鏇顧膚壓餘(鏇積觸鹹廠鑰鹽顧廠築) = one patient experienced grade 1 abdominal pain 網淵繭廠顧鬱廠窪衊鹹 (餘艱簾餘觸憲艱選窪鬱 ) 更多	-	2023-04-23